Wolfe Research Upgrades Abbott Labs and AbbVie to Outperform Amid In-Line Inflation Data
核心洞察
Wolfe Research upgraded Abbott Laboratories to Outperform from Peer Perform, setting a $130 target price on the healthcare and diagnostics company.
AbbVie (搜索) was also upgraded to Outperform from Peer Perform at Wolfe Research, with a $300 target price objective.
The upgrades came as markets rallied broadly after consumer price index data landed in line with expectations at 3.4% year-over-year.
Wolfe Research upgraded two major pharmaceutical and healthcare companies on Thursday, August 13, 2026, lifting Abbott Laboratories (NYSE: ABT) and AbbVie (搜索) (NASDAQ: ABBV) to Outperform from Peer Perform. The analyst actions arrived against a backdrop of broadly rising markets, as traders and investors reacted to an in-line U.S. Consumer Price Index (CPI) inflation report.
Abbott Laboratories received an upgrade to Outperform from Peer Perform at Wolfe Research, which set a $130 target price on the healthcare and diagnostics company. AbbVie (搜索) was likewise upgraded to Outperform from Peer Perform at Wolfe Research, with a $300 target price objective established for the pharmaceutical firm.
The broader market context supported the positive analyst sentiment. The consumer price index data came in right on Wall Street expectations, with a 3.4% year-over-year print and a 0.01% month-over-month increase. Core CPI, which excludes the volatile food and energy costs, rose 2.5%. Following the inline inflation reports, stocks moved higher, with three of the major indices closing up. The small-cap Russell 2000 led the way, closing up 0.63% at 3,046, while the tech-heavy Nasdaq closed at 26,588, up 0.55%, and the S&P 500 closed at 7,748, up 0.26%.
Additional Healthcare Sector Calls
The analyst research activity extended beyond the two upgrades. Stryker (NYSE: SYK) was cut to Peer Perform from Outperform at Wolfe Research, without a price target. Monopar Therapeutics (NASDAQ: MNPR) was downgraded to Neutral from Overweight at Cantor Fitzgerald, which bumped the target price for the shares to $119 from $109.
Alcon (NYSE: ALC) was downgraded to Neutral from Outperform at BNP Paribas, with a $79 target price. These moves reflect a mixed outlook across the healthcare and medical device landscape, even as the two large-cap names received more favorable ratings.
Market Backdrop
The analyst calls came as inflation data continued to shape investor sentiment. The inflation watch was set to continue with the producer price index report at 8:30 AM EDT, with economists predicting a month-over-month headline increase of 0.2% and a core PPI increase of 0.3%. Bond yields across the Treasury curve were mostly flat, with the benchmark 10-year note unchanged on the day at 4.69% and the 30-year long bond finishing at 5.25%.
The upgrades to Abbott Laboratories and AbbVie (搜索) signal renewed analyst confidence in these healthcare names, with both firms receiving Outperform ratings and specific price targets from Wolfe Research as part of Thursday's broader round of Wall Street research calls.